How has been the historical performance of Dr Reddy's Labs?

Revenue and Profit Growth

Over the seven-year period ending March 2025, Dr Reddy's Labs has seen its net sales increase steadily from ₹15,448 crore in 2019 to ₹32,644 crore in 2025. This represents a compound growth trajectory reflecting the company's expanding market presence and product portfolio. Operating profit before other income (PBDIT excl OI) also rose significantly, reaching ₹8,547 crore in 2025 from ₹3,178 crore in 2019, indicating improved operational efficiency despite rising costs.

The operating profit margin, excluding other income, has fluctuated but remained robust, peaking at 28.4% in 2024 before settling at 26.3% in 2025. Gross profit margins followed a similar pattern, underscoring the company's ability to manage production and raw material costs effectively.

Profit after tax (PAT) has more than doubled from ₹1,906 crore in 2019 to ₹5,704 crore in 2025, with the consolidated net profit closely mirroring this trend. The PAT margin improved from 12.7% in 2019 to 17.6% in 2025, reflecting stronger bottom-line growth relative to revenue expansion.

Cost Structure and Expenses

Raw material costs have increased in line with sales growth, rising from ₹2,889 crore in 2019 to ₹5,684 crore in 2025. Similarly, purchases of finished goods have nearly tripled over the same period. Employee costs have also escalated, reflecting the company's investment in talent and capacity expansion, reaching ₹5,580 crore in 2025 from ₹3,356 crore in 2019.

Notably, selling and distribution expenses were reported only from 2020 onwards, increasing steadily to ₹5,947 crore in 2023, though no figures were reported for 2024 and 2025. Other expenses showed significant variation, with a marked increase to ₹8,537 crore in 2025, which may include various operational and administrative costs.

Balance Sheet Strength and Asset Base

Dr Reddy's Labs has expanded its asset base substantially, with total assets rising from ₹22,005 crore in 2020 to ₹47,594 crore in 2025. Net block, representing fixed assets net of depreciation, more than doubled from ₹6,850 crore in 2020 to ₹18,226 crore in 2025, signalling ongoing capital investments.

Shareholders' funds have grown consistently, reaching ₹33,550 crore in 2025 from ₹15,599 crore in 2020, supported by increasing reserves. The company has maintained a manageable debt profile, with total debt reducing to zero in 2025 after peaking at over ₹3,000 crore in 2022. This deleveraging enhances financial flexibility and reduces interest burden, which stood at ₹283 crore in 2025.

Cash Flow and Liquidity

Operating cash flow has shown a positive trend, with cash generated from operations increasing to ₹4,642 crore in 2025 from ₹2,984 crore in 2020. Despite significant investing outflows related to capital expenditure, the company managed to maintain positive net cash inflows, aided by financing activities that contributed ₹1,891 crore in 2025.

Closing cash and cash equivalents surged to ₹1,459 crore in 2025, more than doubling from ₹710 crore in 2024, indicating improved liquidity and cash management.

Valuation Metrics and Shareholder Returns

Earnings per share (EPS) have shown variability due to changes in face value and other factors, with a notable peak in 2023. Adjusted book value per share has increased steadily, reflecting the company's growing net worth and retained earnings. The consistent rise in reserves and shareholder equity underscores Dr Reddy's Labs' capacity to generate shareholder value over time.

Overall, the historical performance of Dr Reddy's Labs reveals a company that has successfully expanded its revenue base, improved profitability, and strengthened its financial position while maintaining prudent debt levels and healthy cash flows. These factors collectively position the company favourably within the pharmaceutical sector.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →